<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial regimens for children with acute unilateral cervical lymphadenitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial regimens for children with acute unilateral cervical lymphadenitis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial regimens for children with acute unilateral cervical lymphadenitis</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Antimicrobial therapy</td> <td class="subtitle1">Dose<sup>*</sup></td> <td class="subtitle1">Spectrum</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Oral therapy</td> </tr> <tr> <td class="indent1">Amoxicillin-clavulanate<sup>¶</sup> <ul class="decimal_heading"> <li>125 mg/5 mL suspension</li> <li>250 mg/5 mL suspension</li> <li>250 mg tablet<sup>Δ</sup></li> <li>500 mg tablet</li> </ul> </td> <td>40 mg/kg per day orally divided every 8 hours (maximum 1.5 g/day)</td> <td> <p>MSSA</p> <p>GAS</p> Oral anaerobes</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class="indent1">Amoxicillin-clavulanate<sup>¶</sup> <ul class="decimal_heading"> <li>200 mg/5 mL suspension</li> <li>400 mg/5 mL suspension</li> <li>200 mg chewable tablet</li> <li>400 mg chewable tablet</li> </ul> </td> <td>25 to 45 mg/kg per day orally divided every 12 hours (maximum 1.75 g/day)</td> <td> <p>MSSA</p> <p>GAS</p> Oral anaerobes</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class="indent1">Cefadroxil</td> <td>30 mg/kg per day orally divided every 12 hours (maximum 2 g/day)</td> <td> <p>MSSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Cephalexin</td> <td>25 to 100 mg/kg per day orally divided every 6 or 8 hours (maximum 4 g/day)</td> <td> <p>MSSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Clindamycin<sup>◊</sup></td> <td>30 mg/kg per day orally divided every 6 or 8 hours (maximum 1.8 g/day)</td> <td> <p>MSSA<sup>◊</sup></p> <p>MRSA<sup>◊</sup></p> <p>GAS</p> Oral anaerobes</td> <td> <p>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</p> Oral suspension may be unpalatable, affecting adherence</td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole<sup>§</sup> (TMP-SMX, cotrimoxazole)</td> <td>10 mg/kg per day orally divided every 12 hours (maximum 320 mg/day)</td> <td> <p>MSSA</p> <p>MRSA</p> <em>Bartonella henselae</em></td> <td>Not active against GAS, so should not be used for empiric therapy</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Parenteral therapy</td> </tr> <tr> <td class="indent1">Ampicillin-sulbactam<sup>¶</sup></td> <td>100 to 200 mg/kg per day IV divided every 6 hours (maximum 8 g/day of ampicillin component)</td> <td> <p>MSSA</p> <p>GAS</p> <p>Oral anaerobes</p> Gram-negative organisms</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class="indent1">Cefazolin</td> <td>50 to 100 mg/kg per day IV divided every 8 hours (maximum dose 6 g/day)</td> <td> <p>MSSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Clindamycin<sup>◊</sup></td> <td>40 mg/kg per day IV divided every 6 or 8 hours (maximum 2.7 g/day)</td> <td> <p>MSSA<sup>◊</sup></p> <p>MRSA<sup>◊</sup></p> <p>GAS</p> Oral anaerobes</td> <td> <p>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</p> Preferred in communities with low<sup>◊</sup> prevalence of clindamycin-resistant <em>S. aureus</em></td> </tr> <tr> <td class="indent1">Linezolid</td> <td> <p>&lt;12 years: 30 mg/kg per day IV divided every 8 hours (maximum 1.8 g/day)</p> ≥12 years: 20 mg/kg per day IV divided every 12 hours (maximum 1.2 g/day)</td> <td> <p>MSSA</p> <p>MRSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Nafcillin</td> <td>150 to 200 mg/kg per day IV divided every 4 or 6 hours (maximum dose 12 g/day)</td> <td> <p>MSSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Oxacillin</td> <td>150 to 200 mg/kg per day IV divided every 4 or 6 hours (maximum dose 12 g/day)</td> <td> <p>MSSA</p> GAS</td> <td> </td> </tr> <tr> <td class="indent1">Piperacillin-tazobactam<sup>¥</sup></td> <td>300 mg/kg per day IV divided every 6 or 8 hours (maximum dose 16 g/day of piperacillin component)</td> <td> <p>MSSA</p> <p>GAS</p> <p>Oral anaerobes</p> Gram-negative organisms</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class="indent1">Vancomycin</td> <td>45 to 60<sup>‡</sup>mg/kg per day IV divided every 6 or 8 hours (maximum 4 g/day)</td> <td> <p>MSSA</p> <p>MRSA</p> GAS</td> <td>Preferred in communities with substantial<sup>◊</sup> prevalence of clindamycin-resistant <em>S. aureus</em></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>GAS: group A <em>Streptococcus</em>; IV: intravenously; MRSA: methicillin-resistant <em>S. aureus</em>; MSSA: methicillin-susceptible <em>Staphylococcus aureus</em>.</p>
<p>* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</p>
<p>¶ Dosed according to the amoxicillin or ampicillin component. The choice of which amoxicillin-clavulanate dosing regimen (every 8 hours or every 12 hours) to use is made based on availability of the various formulations and provider and caregiver preferences.</p>
<p>Δ This tablet is only for children who weigh ≥40 kg.</p>
<p>◊ The prevalence of clindamycin-resistant <em>S. aureus</em> varies geographically and may be more than 10% in some communities. The threshold prevalence of clindamycin-resistant <em>S. aureus</em> for choosing vancomycin varies from center to center, usually ranging from 10 to 25%, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community.</p>
<p>§ Dosed according to the trimethoprim component.</p>
<p>¥ Dosed according to the piperacillin component.</p>
‡ 60 mg/kg per day is recommended for children with serious infections (eg, toxic-appearing, fluctuant nodes, concomitant cellulitis). Adjustment of dose and frequency may be necessary based upon serum concentration monitoring.</div><div id="graphicVersion">Graphic 97715 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
